Triflusal for preventing serious vascular events in people at high risk
Sübutlu məlumatların xülasələri
30.08.2018 • Sonuncu dəyişiklik 30.08.2018
Editors
Triflusal appears to have similar effect to aspirin in secondary prevention of serious vascular events in patients with stroke or TIA and AMI, with a lower risk of hemorrhagic complications.
A Cochrane review included 7 studies with a total of 5 622 subjects.
Aspirin versus triflusal (4 trials enrolling patients with stroke or transient ischemic attack, n=2 944, followed for 6 to 47 months; and 1 trial enrolling patients with AMI, n=2 275, followed for 35 days)
- For the primary outcome of a serious vascular event there was no significant difference between triflusal and aspirin; the odds ratio (OR) was 1.04 (95% confidence interval (CI) 0.87 to 1.23). Significant differences were found for frequency of hemorrhages, both minor (OR 1.60, 95% CI 1.31 to 1.95) and major (OR 2.34, 95% CI 1.58 to 3.46) and for non-hemorrhagic gastrointestinal adverse events (OR 0.84, 95% CI 0.75 to 0.95). Sensitivity analysis of well versus poorly allocated trials showed no significant differences.
Triflusal versus placebo (2 trials enrolling patients with unstable angina, n=281, or peripheral arteriopathy, n=122, followed for 6 months)
- Triflusal was associated with a reduction in serious vascular events (OR 2.29, 95% CI 1.01 to 5.19; OR greater than 1 favours triflusal) and with a higher frequency of adverse events (OR 1.68, 95% CI 1.00 to 2.80).
Ədəbiyyat
- Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005 Jul 20;(3):CD004296.